Opko Health, Inc. Form 4
October 21, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading FROST PHILLIP MD ET AL Issuer Symbol Opko Health, Inc. [OPK] (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) _X__ Director X__ 10% Owner X_ Officer (give title _ Other (specify OPKO HEALTH, INC., 4400 10/18/2013 below) BISCAYNE BLVD. CEO & Chairman (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) Form filed by One Reporting Person X_ Form filed by More than One Reporting **MIAMI, FL 33137** Person

| (City) | (State) | (Zip) Tab | le I - Non- | Derivativ | e Secu | rities Acqui | red, Disposed of, | or Beneficiall | y Owned |
|--------------------------------------|--------------------------------------|---|--|-------------------------|------------------------------|--------------|--|--|---|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transactic Code (Instr. 8) | omr Dispo (Instr. 3, | sed of 4 and (A) or | ` ′ | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Common Stock | 10/18/2013 | | P | 2,000 | A | \$ 11.43 | 136,811,659 | I | See Footnote (1) |
| Common Stock | 10/18/2013 | | P | 100 | A | \$ 11.675 | 136,811,759 | I | See Footnote (1) |
| Common Stock | 10/18/2013 | | P | 600 | A | \$ 11.68 | 136,812,359 | I | See Footnote (1) |
| Common Stock | 10/18/2013 | | P | 1,300 | A | \$ 11.69 | 136,813,659 | I | See Footnote |

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Edgar Filing: Opko Health, Inc. - Form 4

| | | | | | | | | <u>(1)</u> |
|-----------------|------------|---|-------|---|---------------|-------------|---|------------------|
| Common Stock | 10/18/2013 | P | 2,900 | A | \$ 11.7926 | 136,816,559 | I | See Footnote |
| Common Stock | 10/18/2013 | P | 100 | A | \$ 11.81 | 136,816,659 | I | See Footnote |
| Common Stock | 10/18/2013 | P | 1,600 | A | \$ 11.92 | 136,818,259 | I | See Footnote |
| Common Stock | 10/18/2013 | P | 300 | A | \$ 11.93 | 136,818,559 | I | See Footnote |
| Common Stock | 10/18/2013 | P | 500 | A | \$ 11.9597 | 136,819,059 | I | See Footnote (1) |
| Common Stock | 10/18/2013 | P | 6,400 | A | \$ 11.96 | 136,825,459 | I | See Footnote (1) |
| Common Stock | 10/18/2013 | P | 400 | A | \$ 11.97 | 136,825,859 | I | See Footnote |
| Common Stock | 10/18/2013 | P | 500 | A | \$ 11.98 | 136,826,359 | I | See Footnote |
| Common Stock | 10/18/2013 | P | 600 | A | \$ 11.9928 | 136,826,959 | I | See Footnote |
| Common Stock | 10/18/2013 | P | 4,700 | A | \$ 12 | 136,831,659 | I | See Footnote |
| Common Stock | 10/18/2013 | P | 700 | A | \$ 12.01 | 136,832,359 | I | See Footnote |
| Common Stock | | | | | | 15,490,546 | I | See Footnote |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Edgar Filing: Opko Health, Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

| 1. Title of | 2. | 3. Transaction Date | 3A. Deemed | 4. | 5. | 6. Date Exerc | cisable and | 7. Titl | le and | 8. Price of | 9 |
|-------------|-------------|---------------------|--------------------|------------|------------|---------------|-------------|---------|--------------|-------------|---|
| Derivative | Conversion | (Month/Day/Year) | Execution Date, if | Transact | ionNumber | Expiration Da | ate | Amou | int of | Derivative | J |
| Security | or Exercise | | any | Code | of | (Month/Day/ | Year) | Under | lying | Security | , |
| (Instr. 3) | Price of | | (Month/Day/Year) | (Instr. 8) | Derivative | e | | Secur | ities | (Instr. 5) |] |
| | Derivative | | | | Securities | | | (Instr. | 3 and 4) | | (|
| | Security | | | | Acquired | | | | | | J |
| | - | | | | (A) or | | | | | | J |
| | | | | | Disposed | | | | | | - |
| | | | | | of (D) | | | | | | (|
| | | | | | (Instr. 3, | | | | | | |
| | | | | | 4, and 5) | | | | | | |
| | | | | | | | | | Amount | | |
| | | | | | | | | | Amount | | |
| | | | | | | Date | Expiration | Title | or Number | | |
| | | | | | | Exercisable | Date | Title | of | | |
| | | | | C-1- 1 | 7 (A) (D) | | | | | | |
| | | | | Code V | (A) (D) | | | | Shares | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|---|---------------|-----------|----------------|-------|--|--|--|
| r | Director | 10% Owner | Officer | Other | | | |
| FROST PHILLIP MD ET AL OPKO HEALTH, INC. 4400 BISCAYNE BLVD. MIAMI, FL 33137 | X | X | CEO & Chairman | | | | |
| Frost Gamma Investments Trust 4400 BISCAYNE BLVD. MIAMI, FL 33137 | | X | | | | | |
| Signatures | | | | | | | |

Signatures

Phillip Frost, M.D., Individually and as Trustee 10/21/2013

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial

The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and

to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

These securities are owned directly by The Frost Group, LLC. Frost Gamma Investments Trust is a principal member of The Frost Group,

(2) LLC. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Reporting Owners 3

Edgar Filing: Opko Health, Inc. - Form 4

| a currently valid OMB number. | |
|-------------------------------|--|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |